Cubist Systematic Strategies, LLC Exelixis, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 264,642 shares of EXEL stock, worth $8.95 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

264,642

Holding current value

$8.95 Million

% of portfolio

0.04%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $5.81 Million - $7.3 Million	264,642 New	264,642 $6.87 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $5.65 Million - $6.71 Million	-280,290 Reduced 52.53%	253,289 $6.01 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $9.39 Million - $11.8 Million	-487,620 Reduced 47.75%	533,579 $12.8 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $10.5 Million - $12.6 Million	553,697 Added 118.44%	1,021,199 $22.3 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $1.38 Million - $1.56 Million	-75,936 Reduced 13.97%	467,502 $8.93 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $7.95 Million - $9.47 Million	487,786 Added 876.49%	543,438 $10.5 Million
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $3.19 Million - $3.7 Million	-213,013 Reduced 79.29%	55,652 $892,000
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $1.6 Million - $2.28 Million	-102,157 Reduced 27.55%	268,665 $4.21 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $732,985 - $973,391	42,029 Added 12.78%	370,822 $7.72 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $3.09 Million - $4.12 Million	181,602 Added 123.38%	328,793 $7.45 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $1.22 Million - $1.68 Million	-76,844 Reduced 34.3%	147,191 $2.69 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $245,282 - $318,114	15,048 Added 7.2%	224,035 $4.74 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $660,829 - $940,991	36,815 Added 21.38%	208,987 $3.81 Million
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $1.69 Million - $2.08 Million	82,296 Added 91.57%	172,172 $3.89 Million
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $2.05 Million - $2.77 Million	-111,676 Reduced 55.41%	89,876 $1.8 Million
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $3.89 Million - $5.07 Million	-188,191 Reduced 48.29%	201,552 $4.93 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $2.88 Million - $4.79 Million	174,720 Added 81.26%	389,743 $9.25 Million
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $2.9 Million - $4.37 Million	200,262 Added 1356.7%	215,023 $3.7 Million
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $173,634 - $216,498	11,461 Added 347.3%	14,761 $260,000
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $503,667 - $645,253	-28,488 Reduced 89.62%	3,300 $58,000
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $1.45 Million - $1.89 Million	-76,393 Reduced 70.62%	31,788 $679,000
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $405,798 - $512,631	20,704 Added 23.67%	108,181 $2.58 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $967,716 - $1.55 Million	70,895 Added 427.54%	87,477 $1.72 Million
Q3 2018 Nov 14, 2018	SELL	$15.87 - $22.4 $18,647 - $26,320	-1,175 Reduced 6.62%	16,582 $294,000
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $168,970 - $204,384	-9,104 Reduced 33.89%	17,757 $382,000
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $489,359 - $704,545	-22,093 Reduced 45.13%	26,861 $595,000
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $217,100 - $277,132	-8,960 Reduced 15.47%	48,954 $1.49 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $1.35 Million - $1.69 Million	57,914	57,914 $1.4 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Exelixis, Inc. Transaction History